Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01598454 : Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
PhasePhase 1
AgesMin: 1 Year Max: 10 Years
Inclusion Criteria:

- Children (both genders) of between 1 and 10 years old at the time of accrual.

- Diagnosis of neuroblastoma (progression after first line treatment), glioma
(progressing disease or metastatic disease, without curative treatment options),
Ewing's sarcoma (progressive metastatic disease to first line treatment or
progressive disease to second line treatment), Wilm's tumor (metastatic relapse after
treatment), or retinoblastoma (progressing disease or metastatic relapse during or
after first line treatment).

- Previous cancer treatment finished 30 days before accrual.

- Lansky performance status over 50.

Exclusion Criteria:

- History of encephalopathy, convulsions, asthma or severe allergy.

- Infectious disease grade 3 or 4 according to CTCAE version 3.

- Hepatic, kidney or cardiac insufficiency.

- Marrow insufficiency after self-transplantation of hematopoietic stem cells.

- Weight inferior to 12 kg at the time of accrual.

- Concomitant cancer treatment.

- Inability to comply with study procedures.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557